Royce & Associates LP Has $9.73 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Royce & Associates LP grew its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 339,529 shares of the specialty pharmaceutical company’s stock after purchasing an additional 33,674 shares during the quarter. Royce & Associates LP’s holdings in Collegium Pharmaceutical were worth $9,728,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of COLL. JPMorgan Chase & Co. lifted its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after purchasing an additional 116,327 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $2,432,000. Principal Financial Group Inc. grew its holdings in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the period. Finally, Janus Henderson Group PLC increased its position in Collegium Pharmaceutical by 399.4% during the third quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after buying an additional 55,572 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.5 %

COLL stock opened at $29.82 on Wednesday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $938.91 million, a price-to-earnings ratio of 12.85 and a beta of 0.99. The business’s fifty day moving average price is $30.89 and its two-hundred day moving average price is $32.81.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.60.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 2,255 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares of the company’s stock, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 over the last 90 days. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.